Terumo (4543) AI Stock Analysis

• Market Cap: $3.79T
• Dividend Yield: 1%
• Average Volume (3M): 3.51M
• Price to Earnings (P/E): 30.3
• Beta (1Y): 0.74
• Revenue Growth: 7.58%
• EPS Growth: 6.74%
• Country: JP
• Employees: 30,207
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 28.37
• Shares Outstanding: 1,480,559,700
• 10 Day Avg. Volume: 3,104,310
• 30 Day Avg. Volume: 3,507,713
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.02
• Enterprise Value/Revenue: 3.74
• Enterprise Value/Gross Profit: 6.91
• Enterprise Value/Ebitda: 15.87
• 1Y Price Target: $3,266.87
• Price Target Upside: 26.11% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 73 Outperform
• Price Target: ¥2,915.00 ▲(12.53% Upside)

Terumo's strong financial performance and positive earnings call sentiment are the primary drivers of its stock score. However, the high P/E ratio and modest dividend yield suggest valuation concerns. Technical indicators show mixed signals, with potential short-term weakness but medium-term support.

Terumo Business Overview & Revenue Model

Company Description

Terumo Corporation engages in the manufacture and sale of medical products and equipment worldwide. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritious food products, adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Terumo Corporation generates revenue primarily through the sale of its medical devices and systems across various healthcare sectors. Its key revenue streams include the Cardiac and Vascular Company, which provides interventional and cardiovascular products; the General Hospital Company, offering infusion systems, nutritional management, and diabetes care products; and the Blood and Cell Technologies Company, which focuses on blood management systems and therapeutic apheresis. Terumo's earnings are bolstered by its global presence, with significant sales in Japan, the Americas, Europe, and Asia. Strategic partnerships and investments in research and development also play a crucial role in driving innovation and expanding its market share.

Terumo Financial Statement Overview

Summary

Terumo demonstrates strong financial health with impressive revenue growth and profitability. The balance sheet is solid with reduced leverage and strong equity. Cash flow generation is excellent, enhancing liquidity and operational flexibility.

Income Statement

Terumo has demonstrated strong revenue growth with a substantial increase of 12.45% in the latest fiscal year. The gross profit margin is robust, indicating effective cost management. Net profit margin improved to 11.29%, reflecting enhanced profitability. Both EBIT and EBITDA margins are solid, showcasing operational efficiency.

Balance Sheet

The balance sheet presents a healthy equity position with an equity ratio of 74.86%, suggesting financial stability. The debt-to-equity ratio has decreased, indicating reduced leverage risk. Return on equity is strong at 8.55%, showing effective use of equity to generate profits.

Cash Flow

Free cash flow has grown significantly by 110.50%, highlighting improved cash generation capabilities. The operating cash flow to net income ratio is 1.80, indicating strong cash generation from operations. The free cash flow to net income ratio is also favorable at 1.22, reinforcing the company's liquidity position.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.04T	1.04T	921.86B	820.21B	703.30B	613.84B
Gross Profit	560.67B	560.67B	454.17B	417.37B	369.34B	326.62B
EBITDA	244.14B	246.74B	197.69B	188.44B	175.55B	151.38B
Net Income	116.98B	116.98B	106.37B	89.33B	88.81B	77.27B
Balance Sheet
Total Assets	1.83T	1.83T	1.83T	1.60T	1.47T	1.35T
Cash, Cash Equivalents and Short-Term Investments	221.87B	221.87B	206.35B	187.43B	205.31B	201.89B
Total Debt	174.84B	174.84B	231.85B	231.94B	226.00B	260.57B
Total Liabilities	459.85B	459.85B	504.31B	491.16B	461.38B	494.53B
Stockholders Equity	1.37T	1.37T	1.33T	1.11T	1.01T	856.66B
Cash Flow
Free Cash Flow	142.19B	142.19B	67.56B	45.36B	67.36B	38.36B
Operating Cash Flow	210.80B	210.80B	146.33B	117.54B	141.47B	121.48B
Investing Cash Flow	-82.48B	-82.48B	-81.47B	-59.12B	-78.45B	-85.32B
Financing Cash Flow	-108.77B	-108.77B	-62.08B	-86.56B	-70.88B	-7.44B

Terumo Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2590.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4543, the sentiment is Negative. The current price of 2590.5 is below the 20-day moving average (MA) of 2668.13, below the 50-day MA of 2591.96, and below the 200-day MA of 2756.74, indicating a bearish trend. The MACD of -11.14 indicates Positive momentum. The RSI at 43.36 is Neutral, neither overbought nor oversold. The STOCH value of 15.35 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4543.

Terumo Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4543	73 Outperform	$3.79T	30.35	9.17%	1.00%	7.58%	6.74%
Sector *	51 Neutral	$7.92B	-0.36	-43.38%	2.24%	22.38%	-2.16%
AHICF	―	$4.95B	58.24	8.67%	0.88%	―	―
HOCPF	―	$49.13B	33.99	21.19%	0.80%	―	―
5FA	―	€1.47B	41.17	2.49%	―	―	―
OCPNF	―	$13.85B	18.99	14.88%	1.06%	―	―
SSMXF	―	$7.98B	25.07	10.48%	1.61%	―	―

Terumo Corporate Events

Terumo Acquires OrganOx to Enter Organ Transplantation Sector

Terumo Corporation has announced its acquisition of OrganOx Limited for approximately USD 1.5 billion, marking its strategic entry into the organ transplantation sector. This move is expected to enhance Terumo’s business portfolio and address significant unmet medical needs by improving organ preservation and utilization rates, ultimately benefiting transplant patients and healthcare providers globally.

The most recent analyst rating on (JP:4543) stock is a Buy with a Yen3165.00 price target. To see the full list of analyst forecasts on Terumo stock, see the JP:4543 Stock Forecast page.

Terumo Corporation Reports Increased Profits and Dividend Guidance

Terumo Corporation reported a modest increase in revenue for the three months ended June 30, 2025, with a 0.7% rise compared to the previous year. However, the company saw significant growth in operating profit and profit before tax, indicating improved operational efficiency. The financial results highlight Terumo’s strong market positioning and its ability to enhance profitability despite a challenging market environment. The company also announced an increase in its annual dividend guidance, reflecting confidence in its financial stability and commitment to shareholder returns.

The most recent analyst rating on (JP:4543) stock is a Buy with a Yen3800.00 price target. To see the full list of analyst forecasts on Terumo stock, see the JP:4543 Stock Forecast page.

Terumo Finalizes Stock Options Issuance Details

Terumo Corporation has finalized the details regarding the issuance of stock options, specifically Share Warrants No.13, as resolved in their July 17, 2025 Board of Directors meeting. The allocation involves 5,233 warrants distributed among group executive officers, executive officers, and fellows, with a subscription price set at 18,960 yen per warrant. This move is likely aimed at incentivizing leadership and aligning their interests with the company’s long-term goals.

The most recent analyst rating on (JP:4543) stock is a Buy with a Yen3800.00 price target. To see the full list of analyst forecasts on Terumo stock, see the JP:4543 Stock Forecast page.

Terumo Completes Disposal of Treasury Shares for Stock Remuneration

Terumo Corporation has completed the disposal of 101,606 treasury shares as part of its Restricted Stock remuneration plan. This move, involving directors, executive officers, Terumo Fellows, and employees, signifies a strategic step in aligning the interests of its key stakeholders with the company’s performance, potentially enhancing its market positioning and operational focus.

The most recent analyst rating on (JP:4543) stock is a Buy with a Yen3800.00 price target. To see the full list of analyst forecasts on Terumo stock, see the JP:4543 Stock Forecast page.

Terumo Corporation Issues Stock Options to Enhance Executive Alignment

Terumo Corporation announced the issuance of stock options in the form of share warrants to its executive officers and fellows residing outside Japan. This initiative aims to align the interests of these key personnel with shareholders, enhancing their motivation to contribute to the company’s stock price appreciation and corporate value. The issuance of these share warrants is part of Terumo’s strategy to strengthen its leadership’s commitment to the company’s growth and operational success.

The most recent analyst rating on (JP:4543) stock is a Buy with a Yen3800.00 price target. To see the full list of analyst forecasts on Terumo stock, see the JP:4543 Stock Forecast page.